Enasidenib in IDH-2 mutant AML patients with relapse after allogeneic stem cell transplantation

Vasova I, Spörl S, Guggenberger V, Berisha M, Rech D, Behzad A, Brandt A, Kremer A, Mackensen A, Rösler W, Winkler J (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Oncology Research and Treatment Karger Publishers

Publisher: KARGER

City/Town: BASEL

Pages Range: 150-150

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

Authors with CRIS profile

Ingrid Vasova Lehrstuhl für Innere Medizin V Silvia Spörl Department of Medicine 5 – Haematology and Oncology Valentin Guggenberger Lehrstuhl für Innere Medizin V Ali Behzad Department of Medicine 5 – Haematology and Oncology Amelie Brandt Lehrstuhl für Innere Medizin III Andreas Mackensen Lehrstuhl für Innere Medizin V Wolf Rösler Department of Medicine 5 – Haematology and Oncology

How to cite

APA:

Vasova, I., Spörl, S., Guggenberger, V., Berisha, M., Rech, D., Behzad, A.,... Winkler, J. (2021). Enasidenib in IDH-2 mutant AML patients with relapse after allogeneic stem cell transplantation. In ONCOLOGY RESEARCH AND TREATMENT (pp. 150-150). BASEL: KARGER.

MLA:

Vasova, Ingrid, et al. "Enasidenib in IDH-2 mutant AML patients with relapse after allogeneic stem cell transplantation." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2021. 150-150.

BibTeX: Download